[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"critically-ill-intensive-care-unit-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:critically-ill-intensive-care-unit-patients":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,44,76,117,146,173,202,231,259],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100642882","fmt-for-feeding-intolerance-due-to-gastrointestinal-dysfunction-in-critically-ill-patients-100642882",false,"NCT07640633","FMT for Feeding Intolerance Due to Gastrointestinal Dysfunction in Critically Ill Patients","Fecal Microbiota Transplantation for Feeding Intolerance Due to Gastrointestinal Dysfunction in Critically Ill Patients: A Single-Center, Single-Blind, Randomized Controlled Trial","FMT-FIT","Inclusion Criteria:\n\n1. Aged 18 to 70 years inclusive, regardless of ethnicity or gender;\n2. Female participants are either non-fertile (i.e., physiologically incapable of pregnancy, including women with ≥2 years of menopause) or have no pregnancy plans;\n3. Have been admitted to the ICU for ≥24 hours;\n4. Expected ICU stay ≥7 days after study enrollment;\n5. Screened positive for ≥1 manifestation of gastrointestinal dysfunction (intra-abdominal hypertension \\[IAH\\], massive gastric retention, diarrhea, lower gastrointestinal paralysis, bowel dilatation); enteral nutrition is then implemented under the guidance of the enteral feeding intolerance (FI) score, and participants with persistent FI after a 3-day trial are formally enrolled;\n6. Participants can actively cooperate or passively complete relevant examinations and follow-up procedures;\n7. Have signed a written informed consent form.\n\nExclusion Criteria:\n\n1. Severe systemic infection in the early resuscitation phase, with hemodynamic instability, insufficient tissue perfusion, or severe fluid-electrolyte and acid-base imbalances;\n2. Patients assessed by clinicians as having a high risk of death within 5 days, or those with restricted treatment decisions;\n3. Active gastrointestinal bleeding, perforation, or other conditions with severe intestinal barrier impairment;\n4. Patients unable to tolerate enteral nutrition meeting 50% of caloric requirements due to severe diarrhea, significant fibrotic intestinal stenosis, massive gastrointestinal bleeding, or high-output enterocutaneous fistula;\n5. Planned or recent abdominal surgery (within 14 days prior to enrollment);\n6. Current diagnosis of fulminant colitis or toxic megacolon;\n7. Neutropenia (neutrophil count \\\u003C 1500 cells\u002FµL);\n8. Patients with congenital or acquired immunodeficiency disorders;\n9. Recent receipt of high-risk immunosuppressive or cytotoxic agents, e.g., rituximab, doxorubicin, or medium-to-high-dose corticosteroids (≥ 20 mg\u002Fday prednisone equivalent) for a duration of \\> 4 weeks;\n10. Pregnant or lactating women;\n11. Participation in another clinical trial as a subject at the time of enrollment or within 3 months prior to enrollment;\n12. Doubtful validity of informed consent: subjects with mental illness, intellectual disability, poor motivation, or other factors that restrict the validity of informed consent for participation in this study.","ALL","18 Years","70 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","Critically ill patients admitted to the intensive care unit (ICU) frequently present with gastrointestinal dysfunction and are at elevated risk of malnutrition. Gastrointestinal dysfunction is correlated with adverse clinical outcomes, including prolonged mechanical ventilation duration, extended ICU length of stay, and increased 90-day mortality.\n\nIn critically ill ICU patients, severe gut microbiota dysbiosis and intestinal barrier impairment may occur due to the burden of primary critical illnesses, as well as the administration of proton pump inhibitors and antibiotics. This cascade contributes to a high prevalence of gastrointestinal dysfunction, alongside profound gut-derived systemic inflammatory responses and organ damage. Given the pivotal role of gut microbiota in maintaining intestinal homeostasis, fecal microbiota transplantation (FMT) holds promise as a novel therapeutic strategy for enteral feeding intolerance secondary to gastrointestinal dysfunction in critically ill ICU patients.\n\nThis study intends to deliver FMT via a nasojejunal tube to critically ill patients with gastrointestinal dysfunction admitted to the ICU. Its objectives are to evaluate the intervention's effects on gastrointestinal function recovery and the alleviation of enteral feeding intolerance, while also assessing its impacts on intestinal barrier function, gut microbiota composition and metabolic profiles, serum metabolite signatures, immune-inflammatory responses (including lymphocyte subsets, cytokines, C-reactive protein, and procalcitonin), ICU delirium, ICU sleep quality, and clinical outcomes (encompassing ICU mortality, in-hospital mortality, 28-day all-cause mortality, 90-day all-cause mortality, 90-day readmission rate, and 90-day incidence of secondary infections).",[28,29,30],"Feeding Intolerance","Gastrointestinal Dysfunction","Critically Ill Intensive Care Unit Patients","NOT_YET_RECRUITING","2026-06-05",{"date":34,"type":35},"2026-06-11","ACTUAL",{"date":37,"type":22},"2026-07-01",{"date":39,"type":22},"2027-06-30",{"name":41,"class":42},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":43},"100600108","rezafungin-peritoneal-diffusion-for-intra-abdominal-candidiasis-100600108","NCT07093203","Rezafungin Peritoneal Diffusion for Intra-abdominal Candidiasis","Pharmacokinetic of Rezafungin in the Plasma and the Peritoneal Fluid of Critically Ill Patients With Intra-abdominal Candidiasis Requiring Abdominal Surgery","REAREZ","Inclusion Criteria:\n\n* age \\> 18 years\n* with a suspected intra-abdominal candidiasis requiring abdominal surgery\n* and receiving the administration of rezafungin as first-line empirical antifungal treatment just before or within 1 hour the abdominal surgery\n* and having abdominal drain for at least 2 days after the surgery\n\nExclusion Criteria:\n\n* death expected within 24h\n* decline to participate",{"count":53,"type":22},20,"OBSERVATIONAL","ntra-abdominal candidiasis is a serious infection common in critically ill patients, often leading to high mortality if not treated quickly. Standard antifungal treatments may be less effective due to growing resistance and poor drug penetration into the abdominal cavity. In critically ill patients, drug levels can vary widely due to factors like surgery, inflammation, fluid resuscitation, or extracorporeal support, increasing the risk of underdosing. Rezafungin is a new antifungal agent with a long half-life and broad activity against Candida species, offering potential advantages in this setting. However, there is currently no data on its concentration or effectiveness in the peritoneal fluid of patients with intra-abdominal sepsis. Its long half-life, coupled with repeated pharmacokinetic variations in critical care settings and the risk of insufficient concentrations, may hinder its use in this population.",[57,58,59,30],"Intra-Abdominal Infection","Candida","Abdominal Surgery Patients",[61,62,63,64,65],"candida","intra-abdominal candidiasis","abdominal surgery","pharmacokinetics","pharmacodynamics","RECRUITING","2026-03-27",{"date":69,"type":35},"2026-04-01",{"date":71,"type":35},"2025-11-14",{"date":73,"type":22},"2026-09-01",{"name":75,"class":42},"Central Hospital, Nancy, France",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":88,"conditions":89,"keywords":95,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100580704","phase-4-effects-of-donor-recipient-sex-matched-blood-transfusion-on-patient-outcomes-100580704","NCT06840756","Effects of Donor-recipient Sex-matched Blood Transfusion on Patient Outcomes","Effects of Donor-recipient Sex-matched Versus Sex-mismatched Red Blood Cell Transfusion on Outcomes in Critically Ill Adult Patients","SexMATTERS RCT","Inclusion Criteria:\n\n* Adults (age ≥18);\n* Admission to a participating ICU;\n* Requiring RBC transfusion.\n\nExclusion Criteria:\n\n* Requirement for a specialized RBC product or unit not readily available in inventory (e.g., rare blood type, washed RBCs, complex RBC antibodies, etc.);\n* Massively bleeding patient (i.e., ≥4 units of blood ordered at one time, or Massive Hemorrhage Protocol initiated, or an urgent blood request made);\n* Sex unknown or sex other than male or female (i.e. intersex);\n* Do not have a valid Ontario Health Insurance Plan (OHIP) health card number.",{"count":85,"type":22},11082,[87],"PHASE4","Red blood cell (RBC) transfusions are selected based upon matching donor and recipient blood group: donor and recipient sex are not considered when selecting blood for transfusion. Hence, transfused patients can currently receive sex-matched and\u002For unmatched RBCs when transfusions are given. Sex-matched stem cell transplants, and some solid organ transplants, have shown that sex-matching donor to recipient improves patient outcomes. Recent exploratory studies have also suggested that patient outcomes could be improved by sex-matching for RBC transfusion. There is emerging evidence of underlying biologic mechanism(s) to support these observations. This study is designed as a randomized controlled trial and will explore the impact on patients who receive RBC transfusions from donors of the same sex (\"sex-matched\") compared with donors of the opposite sex (\"sex-mismatched\").\n\nThe trial will study adult patients admitted to the Intensive Care Unit who require an RBC transfusion. Patients will be assigned (through a process called randomization) to receive sex-matched RBCs or sex-mismatched RBCs to determine if there is a difference in mortality between those receiving matched versus mismatched RBCs. The results of this trial could have direct implications on resources, blood inventory, and RBC transfusion ordering practices.",[90,91,92,30,93,94],"Red Blood Cell Transfusions","Sex Differences","Health Services","Hematology","Cardiovascular",[96,97,98,99,100,101,102,103,104,105,106],"transfusions","red blood cell transfusions","sex-matched","sex-mismatched","intensive care unit","ICU","cardiovascular","circulatory","hematology","mortality","blood donor characteristics","2026-03-10",{"date":109,"type":35},"2026-03-12",{"date":111,"type":35},"2025-09-11",{"date":113,"type":22},"2029-03-31",{"name":115,"class":42},"Michelle Zeller",8,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":23,"phases":125,"briefSummary":126,"conditions":127,"keywords":131,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":43},"100627451","accuracy-and-safety-of-the-syai-tag-system-for-continuous-glucose-monitoring-in-intensive-internal-care-unit-100627451","NCT07448805","Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit","Inclusion Criteria:\n\n* Admission to the intensive care unit\n* Expected ICU stay more than 24 hours\n* Presence of an arterial line\n\nExclusion Criteria:\n\n* Age under 18\n* Pregnancy\n* Skin changes that prevent sensor application",{"count":124,"type":22},100,[25],"Researchers at the Department of Intensive Internal Medicine and the Department of Endocrinology and Diabetology will conduct a study to verify the accuracy and safety of the new Syai Tag system for continuous glucose monitoring in patients in intensive internal care. Almost 150,000 people in Slovenia have diabetes, so keeping a close eye on blood sugar levels is key to preventing complications. The new sensors for continuous monitoring are available over the counter and certified as medical devices. The study will include at least 100 patients who will need blood sugar monitoring during their stay in the intensive care unit. Each patient will have two small sensors placed on each upper arm to continuously measure their blood sugar levels, but these values will not be visible to medical staff. At the same time, healthcare professionals will perform routine blood sugar measurements, and researchers will then compare the accuracy of both methods. The procedure is safe and painless, and patients will receive the same quality of care as usual.",[128,129,130,30],"Diabetes Mellitus","Blood Sugar","Sepsis",[132,133,134,100,135,136],"diabetes mellitus","continuous glucose monitor","blood sugar","sepsis","critically ill intensive care unit patients","2026-02-26",{"date":139,"type":35},"2026-03-04",{"date":141,"type":35},"2026-02-18",{"date":143,"type":22},"2027-05-15",{"name":145,"class":42},"University Medical Centre Maribor",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":154,"targetDuration":156,"studyType":54,"phases":4,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":169,"leadSponsor":171,"locationsCount":43},"100618947","sofa-2-score-in-turkish-icus-100618947","NCT07338240","SOFA-2 Score in Turkish ICUs","Real-Time Validation and Feasibility of the SOFA-2 Score in Adult Intensive Care Units in Türkiye (TR-SOFA2): A Multicenter Prospective Observational Study","TR-SOFA2","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Admission to a participating intensive care unit in Türkiye\n* Intensive care unit stay longer than 24 hours\n\nExclusion Criteria:\n\n* Patients younger than 18 years\n* Pregnant patients\n* Organ donors\n* Patients with unknown intensive care unit discharge outcomes",{"count":155,"type":22},5200,"60 Days","This study aims to evaluate how well a new scoring system called the Sequential Organ Failure Assessment-2 (SOFA-2) works in adult intensive care units in Türkiye.\n\nSOFA-2 is designed to measure the severity of organ dysfunction in critically ill patients using routinely collected clinical and laboratory data. It is an updated version of the original SOFA score and reflects modern intensive care practices.\n\nIn this multicenter observational study, adult patients admitted to participating intensive care units will be followed during their ICU stay. SOFA and SOFA-2 scores will be calculated during the first 24 hours of admission, and in patients with longer stays, additional scores will be recorded. No additional tests or treatments will be performed as part of the study.\n\nThe main goal of the study is to examine the relationship between SOFA-2 scores and intensive care unit mortality. The results are expected to help clinicians better assess disease severity and outcomes in critically ill patients.",[159,30],"Intensive Care Unit Patients",[161,162,163,164],"SOFA-2 Score","Critical Illness","ICU Mortality","Prognostic Scoring System","2026-01-19",{"date":167,"type":35},"2026-01-21",{"date":165,"type":35},{"date":170,"type":22},"2026-07",{"name":172,"class":42},"Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":23,"phases":183,"briefSummary":184,"conditions":185,"keywords":188,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":200,"locationsCount":5},"100600127","quality-improvement-intervention-for-a-safe-antimicrobial-use-reduction-in-critically-ill-patients-100600127","NCT07093450","Quality Improvement Intervention for a Safe Antimicrobial Use Reduction in Critically Ill Patients","Estudo de Implementação de Melhoria de Qualidade Para Redução do Uso de Antimicrobianos em Unidades de Terapia Intensiva","SAFE-REDUCE","Intensive care units inclusion Criteria:\n\n* ICU leadership acceptance to participant in the quality improvement intervention;\n* Hospital infection control leadership acceptance to participant in the quality improvement intervention;\n* ICU participation in the IMPACTO-MR platform with high quality data;\n* ICU potential for quality improvement based on a subjective assessment of the ICU and hospital infection leaderships\n\nIntensive care units exclusion Criteria:\n\n\\- Absence of local IRB approval\n\nParticipants inclusion Criteria:\n\n* All patients admitted to the intensive care unit\n\nParticipants exclusion Criteria:\n\n* Patients younger than 18 years-old will be excluded from individual-level analysis",{"count":182,"type":22},9000,[25],"The goal of this clinical trial is to learn if an educational intervention with audit and feedback on physicians and health care professionals who participate in antimicrobial treatment decisions can reduce the use of antimicrobials in adult patients admitted to a sample of Brazilian intensive care units (ICUs). The educational intervention is based on a literature review of current recommendations for a more rational use of antimicrobials and microbiological tests in daily ICU practice.\n\nThe main questions it aims to answer are:\n\n* Does the educational intervention reduce the antimicrobial consumption in the intensive care units?\n* Does this educational intervention aiming to reduce antimicrobial utilization in accordance with the latest guidelines have any safety signals regarding ICU mortality rates or ICU length-of-stay?\n\nResearchers will compare (1) ICUs sequentially randomized to this quality improvement educational intervention aimed at improving antimicrobial utilization to (2) the same ICUs at months where the educational intervention has not been delivered yet.\n\nEach participant ICU will transition to the quality improvement intervention approximately each month, starting at July, 2025. This quality improvement intervention is based on current recommendations for antimicrobial stewardship from regulatory agencies and medical societies, including cognitive aids for physicians to improve decision-making regarding the commencement of antimicrobials, their duration and antimicrobial time-outs. The investigators hypothesize that intensivists (ICU doctors) need to embrace antimicrobial stewardship as a core competence of their daily activities.",[186,187,30],"Infection","Antimicrobial Stewardship",[189,190,186,191,192,193],"Antimicrobial stewardship","Intensive care unit","Stepped-wedge cluster trials","Hybrid effectiveness-implementation trials","Diagnostic stewardship","2025-11-25",{"date":196,"type":35},"2025-12-03",{"date":198,"type":35},"2025-06-01",{"date":170,"type":22},{"name":201,"class":42},"Hospital Sirio-Libanes",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":23,"phases":212,"briefSummary":214,"conditions":215,"keywords":217,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":230},"100575059","phase-3-ketamine-sedation-in-the-icu-kanine-rct-100575059","NCT06767358","Ketamine Sedation in the ICU (KANINE) RCT","Ketamine Sedation in the Intensive Care Unit: a Pilot Randomized Controlled Trial","KANINE","Inclusion Criteria:\n\n* Adult patients (≥ 18 years) admitted to the ICU\n* Receiving invasive mechanical ventilation and expected to remain mechanically ventilated beyond the calendar day after randomization\n* Mechanically ventilated for fewer than 3 days\n* Receiving any non-ketamine continuous sedative infusion\n\nExclusion Criteria:\n\n* Admitted with a primary diagnosis of intracranial hemorrhage, traumatic brain injury, or stroke\n* Admitted with uncontrolled hypertension (SBP\u002FDBP \\> 180\u002F100mmHg)\n* Status asthmaticus\n* Admitted to the ICU with partial thickness burns \\> 10% total body surface area or any full thickness burns\n* Schizophrenia\n* End-stage Liver Failure (Child-Pugh C)\n* Requiring an equivalent of norepinephrine at a dose ≥1mcg\u002Fkg\u002Fmin\n* Undergoing palliation or comfort care\n* On neuromuscular blocking agent\n* Pre-existing tracheostomy\n* Hypersensitivity to Ketamine\n* Liver transplantation in the last month\n* Pregnant or breast-feeding",{"count":211,"type":22},54,[213],"PHASE3","Sedation is given to intensive care unit (ICU) patients to treat discomfort, anxiety, agitation, and to help facilitate care, particularly when they require a breathing tube. Sedation is very commonly used in the ICU with North American data showing almost 40% of ICU patients get sedation to help when they are requiring a breathing machine. Various medications can be given intravenously to provide sedation in the ICU but there are side-effects associated with each such as decreasing a patient's own drive to breathe, and delirium or acute confusion, both of which are associated with worse outcomes. Also, most drugs used for sedation don't treat pain. As a result, many ICU patients are also given narcotics for pain control which can result in tolerance, dependence, and withdrawal. Ketamine is a sedating medication that also treats pain and is often used in the Emergency Department and in the Operating Room but for whatever reason is not commonly used in the ICU.\n\nThe investigators are proposing a study to examine the usefulness and safety of adding an intravenous infusion of ketamine to usual care in adult patients that are on a breathing machine in the ICU.\n\nStudy Methods The KANINE study is being done at hospitals across Ontario, Canada. It is a randomized controlled trial which means patients will be randomized (akin to a coin flip) to receive ketamine or usual care without ketamine. The study will be blinded which means that neither patients or the doctors will know if the patient is getting ketamine or not, those that get randomized to usual care without ketamine will get an intravenous solution that looks the same as the ketamine infusion. This is important to make sure the results aren't biased in any way. The investigators will include adult ICU patients on a breathing machine who are early in their ICU admission. As most patients will be unconscious, the investigators will ask substitute decision makers (families or caregivers) of patients for informed consent prior to the study commencing. Regardless of whether patients get randomized to ketamine or not, the investigators will make sure that all patients will be adequately sedated and have their pain managed as per usual care.\n\nSetting This study will be performed in adult ICUs across Canada.\n\nPopulation The investigators will include adults admitted to the ICU on a breathing machine and expected to remain mechanically ventilated beyond the calendar day after randomization. The investigators will exclude patients if: (i) they were admitted with a brain bleed, traumatic brain injury, or stroke; (ii) Admitted with uncontrolled high blood pressure; (iii) admitted with status asthmaticus; (iv); admitted to the ICU with partial thickness burns greater than 10% total body surface area or any full thickness burns; (v) if they have a history of schizophrenia; (vi) if they have very bad liver failure; (vii) if they are palliative or only for comfort care; (viii) if they are requiring very high doses of blood pressure support medication to increase their blood pressure; (ix) if they are receiving a medication that causes paralysis, sometimes used in patients with very bad lung disease; (x) if they have a tracheostomy which means a whole in their neck that they breathe through; (xi) if they are allergic to ketamine; (xii) if they've had a liver transplant in the last month; (xiii) if they are pregnant or breast-feeding.\n\nOutcomes The investigators will follow all the study patients to see if their outcomes are different depending on whether they get randomized to ketamine or not. The investigators will capture how much time they are on the breathing machine, whether they survive or die, how long they stay in the ICU and whether they require a tracheostomy which is a procedure often done on patients who require the breathing machine over a prolonged period of time.\n\nThe investigators will also capture how often they get delirious and for those that get delirious how long it lasts for. The investigators will capture how much of other sedating medications study patients use such as antipsychotics and benzodiazepines. The investigators will capture outcomes such as how often study patients get post-traumatic stress disorder after leaving the ICU and how well their pain relief is addressed during their ICU stay. Finally, the investigators will capture side effects related to ketamine or other sedating drug use.",[216,30],"Mechanical Ventilation",[218,219,100,220],"sedation","mechanical ventilation","critically ill","2025-09-16",{"date":223,"type":35},"2025-09-22",{"date":225,"type":22},"2025-10",{"date":227,"type":22},"2027-12",{"name":229,"class":42},"McMaster University",3,{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":23,"phases":240,"briefSummary":241,"conditions":242,"keywords":245,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":43},"100595407","continuous-passive-motion-to-prevent-ankle-contracture-and-muscle-atrophy-in-ventilated-patients-100595407","NCT07032051","Continuous Passive Motion to Prevent Ankle Contracture and Muscle Atrophy in Ventilated Patients","Preventive Effects of Continuous Passive Motion on Ankle Contracture and Muscle Atrophy in Mechanically Ventilated Patients: A Pilot Study","CPM-ICU","Inclusion Criteria:\n\n\\- Eligible participants were adults (≥18 years) with acute respiratory failure expected to require mechanical ventilation for \\>5 days.\n\nExclusion Criteria:\n\n* Neuromuscular disorders\n* Recent lower limb surgery or trauma\n* Critical limb ischemia\n* Limb amputation\n* Deep vein thrombosis\n* Significant leg wounds\n* Pregnancy.",{"count":53,"type":22},[25],"This clinical trial aims to evaluate whether continuous passive motion (CPM) can prevent ankle joint contracture and muscle atrophy in critically ill patients receiving mechanical ventilation in the ICU. The study will also assess the feasibility and safety of implementing CPM therapy in this population.\n\nThe primary objectives are:\n\nTo determine whether CPM preserves ankle dorsiflexion range of motion during ICU immobilization.\n\nTo assess whether ultrasound can detect changes in tibialis anterior muscle morphology in response to CPM.\n\nIn this within-subject design, each participant will receive CPM therapy on one ankle while the contralateral ankle serves as the control. Outcomes related to joint mobility and muscle condition will be compared between the two sides.\n\nParticipants will:\n\nReceive CPM treatment on one ankle for 30 minutes, twice daily, for up to 7 days or until ICU discharge.\n\nUndergo goniometric and ultrasound assessments at baseline and after the intervention.\n\nContinue to receive standard ICU care throughout the study period.",[243,30,244],"Ankle Contracture","Muscle Atrophy",[246,247,248,249],"ICU-acquired weakness","muscle ultrasound","ankle contracture","continuous passive motion,","2025-06-26",{"date":252,"type":35},"2025-06-29",{"date":254,"type":22},"2025-06-25",{"date":256,"type":22},"2025-12-31",{"name":258,"class":42},"Shin Kong Wu Ho-Su Memorial Hospital",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":265,"targetDuration":266,"studyType":54,"phases":4,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":278,"locationsCount":43},"100576945","blood-ddpcr-for-early-identification-and-dynamic-surveillance-of-pathogenic-bacteria-in-icu-septic-patients-a-single-centre-prospective-observational-study-100576945","NCT06791889","Blood DdPCR for Early Identification and Dynamic Surveillance of Pathogenic Bacteria in ICU Septic Patients: a Single-centre, Prospective, Observational Study","Inclusion Criteria:\n\n* Patients with first diagnosis of sepsis after ICU admission\n\nExclusion Criteria:\n\n* Age under 18 years\n* Do not meet Sepsis 3.0 diagnostic criteria\n* Refusal to sign informed consent",{"count":21,"type":22},"1 Month","The purpose of this study is to investigate the efficacy of droplet digital PCR (ddPCR) in identifying pathogenic organisms in ICU sepsis patients, aiming to find a method that allows early identification of pathogenic organisms and dynamic surveillance in order to assess the association between pathogenic species and loads and clinical characteristics and outcomes.",[130,269,30],"Bloodstream Infections",[271,130,101],"ddPCR","2025-03-12",{"date":274,"type":35},"2025-03-17",{"date":276,"type":35},"2024-09-15",{"date":256,"type":22},{"name":41,"class":42}]